OMER
$13.55
Omeros
$.43
3.28%
OMER
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  ($0.32)
Revenue:  $31.38 Mil
Friday
Feb 28
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when OMER reports earnings?
Beat
Meet
Miss

Where is OMER's stock price going from here?
Up
Flat
Down
Stock chart of OMER
Analysts
Summary of analysts' recommendations for OMER
Score
Grade
Pivots
Resistance
$14.08
$13.66
$13.39

$12.97

Support
$12.70
$12.28
$12.01
Tweet
Growth
Description
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
Peers
BioMarin PharmaceuticalRegeneron PharmaceuticalsVertex PharmaceuticalsInterCeptJohnson & JohnsonMylanZoetisUltragenyx PharmaceuticalBristol-Myers SquibbAlkermes